The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...

NORTHAMPTON, MA / ACCESS Newswire / June 3, 2025 / By Guy Diedrich, Ph.DIn every corner of the globe, digital technology is becoming the bridge to opportunity, empowerment, and transformation. Cisco's ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma.

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...

Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.